Skip Navigation

Japanese Journal of Clinical Oncology 2008 38(9):589-595; doi:10.1093/jjco/hyn078
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Seo, M.-D.
Right arrow Articles by Bang, Y.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seo, M.-D.
Right arrow Articles by Bang, Y.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer

Myung-Deok Seo1, Keun-Wook Lee2, Joo Han Lim3, Hyeon Gyu Yi3, Dae-Young Kim3, Do-Youn Oh3, Jee Hyun Kim2, Seock-Ah Im3, Tae-You Kim3, Jong Seok Lee2 and Yung-Jue Bang3

1 Department of Internal Medicine, Cheju National University Hospital, Jeju
2 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam
3 Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

For reprints and all correspondence: Keun-Wook Lee, Department of Internal Medicine, Seoul National University Bundang Hospital 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeongi-do 463-707, Republic of Korea. E-mail: hmodoctor{at}hanmail.net

Received May 13, 2008; accepted July 17, 2008

Objective: We analysed the efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) chemotherapy as second-line treatment for metastatic or relapsed gastric cancer (MRGC) in a clinical practice setting. Factors to select patients who may benefit from salvage chemotherapy was also analysed.

Methods: Patients with MRGC with progression on or within 6 months after discontinuing platinum-based chemotherapy received FOLFIRI as second-line therapy. The FOLFIRI regimen consisted of irinotecan (180 mg/m2; day 1) combined with leucovorin (200 mg/m2), followed by 5-fluorouracil (400 mg/m2) as a bolus and 600 mg/m2 as a 22-h infusion on days 1 and 2 every 2 weeks.

Results: Fifty-one patients received a total of 282 courses of chemotherapy. No patients had complete remission (CR), but 9 patients achieved partial remission (PR). Stable disease (SD) was documented in 15 patients. The median progression-free survival (PFS) and overall survival (OS) were 3.2 and 9.1 months, respectively. Toxicities were tolerable and grade 3/4 neutropenia was observed in 49 cycles (17%). In multivariate analysis, patients with less organ involvement by metastasis and good performance status (PS) were independently associated with a longer PFS and OS (P < 0.05). Disease control (CR, PR or SD) after first-line chemotherapy were related to a longer PFS (P = 0.02), but had no effect on OS.

Conclusions: FOLFIRI was tolerable and showed modest activity as a second-line therapy in MRGC. Less organ involvement by metastasis or good PS may be optimal selection criteria for patients with MRGC who are suitable for second-line chemotherapy.

Key Words: gastric cancer • chemotherapy • second-line • irinotecan • FOLFIRI


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.